Up next

Global API Outlook: Will Supply Lines Change Amid Tariff Uncertainty? 

As evolving US trade policy looms, what are the demand–supply fundamentals now in the global market for active pharmaceutical ingredients (APIs)?  A look at the demand side—size, growth rates, and trends— and the supply side—key segments for global API manufacturing and its geographic dispersion. Plus, examining the impact of potential tariffs on manufacturing and supply chains.  

Julia Morilla, Associate Content Analyst, Cortellis Product Intelligence, Clarivate

Featuring Julia Morilla, Associate Content Analyst, Cortellis Product Intelligence, Clarivate, a business intelligence firm serving the life sciences and bio/pharmaceutical industries.

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights. Or get each episode through:

For a full list of the 2025 podcast episode schedule, click here.

You May Also Like

Biomanufacturing: Capacity Trends & CDMO Insights

By
Sponsored by Lonza AG What is the state-of-the state for biomanufacturing (drug substance) in terms of industry capacity utilization, in-sourced/outsourced activity, and technology drivers? Is capacity in line with demand…

Beyond ADCs: Next-Generation Drug Conjugates

By
Sponsored by Lonza AG Next-generation complex conjugates, such as peptide conjugates, radioconjugates, ligand-conjugated antisense medicines, and small-molecule drug conjugates, are expected to outpace growth comparative to antibody drug conjugates (ADCs),…

New Excipient Products: Are They Coming?

By
Innovation in excipients is important to optimize a drug formulation, but there are barriers to innovation, including regulatory barriers, which excipient manufacturers and users are seeking to address. Providing the…

Pipeline Potential: Small-Molecule Drugs

By
New drug classes–proteolysis-targeting chimeras (PROTACs) and molecular glue degraders–are potentially a new source of product innovation for small-molecule drugs in their ability to reach previously “undruggable” drug targets. There have…